Business
DICOT: Over 80% of the rights issue is secured, ensuring funding for the planned phase 2b study
DICOT: Over 80% of the rights issue is secured, ensuring funding for the planned phase 2b study
About this update from Dicot Pharma Ab
Major shareholders and institutional investors have committed or indicated interest for over 80% of the ongoing rights issue, securing funding for a phase 2b study. A company presentation and Q&A will be held, and the offering is limited to Sweden.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.